文献速递神经肿瘤

应用7.0T弛豫补偿多池CEST MRI评估胶质瘤患者IDH突变和MGMT甲基化状态的可预测性

Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
PubMed 文献 · Neuro Oncol · 2018-01-01

这项前瞻性研究纳入31例新诊断胶质瘤患者,在7T全身扫描仪上行弛豫补偿多池CEST MRI,定量分析NOE和dns-APT信号(均值及90百分位)预测IDH突变、MGMT启动子甲基化及区分低级别与高级别胶质瘤的能力,并与3T先进MRI方法比较。dns-APT对IDH突变预测AUC最高(均值91.84%,P<0.01;90百分位97.96%,P<0.001),并能显著区分低级别与高级别胶质瘤(AUC 0.78和0.83,P<0.05);MGMT甲基化状态在各对比均无显著差异(P>0.05)。作者认为dns-APT成像可作为无创MR生物标志物用于诊断评估。

要点

  • dns-APT均值预测IDH突变AUC为91.84%(P<0.01),90百分位AUC为97.96%(P<0.001)。
  • dns-APT均值区分低级别与高级别胶质瘤AUC为0.78(P<0.05),90百分位AUC为0.83(P<0.05)。
  • MGMT启动子甲基化状态在各对比均无显著差异(P>0.05)。

核心结论

  • 弛豫补偿多池CEST MRI尤其是dns-APT成像能够预测IDH突变状态并区分低级别与高级别胶质瘤,作者认为应将其视为诊断评估中的无创MR生物标志物。

研究设计与样本

  • 前瞻性研究纳入31例新诊断胶质瘤患者,在7T全身扫描仪上行弛豫补偿多池CEST MRI,定量分析整个肿瘤区域的NOE和dns-APT信号(均值和90百分位),并与3T先进MRI方法(表观扩散系数和相对脑血容量)的ROC/AUC分析比较。

主要发现

  • dns-APT均值预测IDH突变AUC为91.84%(P<0.01),dns-APT90预测IDH突变AUC为97.96%(P<0.001)。
  • dns-APT均值区分低级别与高级别胶质瘤AUC为0.78(P<0.05),dns-APT90区分低级别与高级别胶质瘤AUC为0.83(P<0.05)。
  • MGMT启动子甲基化状态在各对比均无显著差异(P>0.05)。

临床怎么用

  • 作者认为弛豫补偿多池CEST MRI尤其是dns-APT成像可作为无创MR生物标志物用于诊断评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early identification of prognostic superior characteristics in glioma patients such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is of great clinical importance. The study purpose was to investigate the non-invasive predictability of IDH mutation status, MGMT promoter methylation, and differentiation of low-grade versus high-grade glioma (LGG vs HGG) in newly diagnosed patients employing relaxation-compensated multipool chemical exchange saturation transfer (CEST) MRI at 7.0 Tesla. METHODS: Thirty-one patients with newly diagnosed glioma were included in this prospective study. CEST MRI was performed at a 7T whole-body scanner. Nuclear Overhauser effect (NOE) and isolated amide proton transfer (APT; downfield NOE-suppressed APT = dns-APT) CEST signals (mean value and 90th signal percentile) were quantitatively investigated in the whole tumor area with regard to predictability of IDH mutation, MGMT promoter methylation status, and differentiation of LGG versus HGG. Statistics were performed using receiver operating characteristic (ROC) and area under the curve (AUC) analysis. Results were compared with advanced MRI methods (apparent diffusion coefficient and relative cerebral blood volume ROC/AUC analysis) obtained at 3T. RESULTS: dns-APT CEST yielded highest AUCs in IDH mutation status prediction (dns-APTmean = 91.84%, P < 0.01; dns-APT90 = 97.96%, P < 0.001). Furthermore, dns-APT metrics enabled significant differentiation of LGG versus HGG (AUC: dns-APTmean = 0.78, P < 0.05; dns-APT90 = 0.83, P < 0.05). There was no significant difference regarding MGMT promoter methylation status at any contrast (P > 0.05). CONCLUSIONS: Relaxation-compensated multipool CEST MRI, particularly dns-APT imaging, enabled prediction of IDH mutation status and differentiation of LGG versus HGG and should therefore be considered as a non-invasive MR biomarker in the diagnostic workup.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Paech D, Windschuh J, Oberhollenzer J, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol. 2018. PMID: 29733378. doi:10.1093/neuonc/noy073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。